Serum biomarkers for prediction and diagnosis of preeclampsia; a meta-analysis, data set.

This meta-analysis was conducted to determine the diagnostic utility of serum biomarkers in preeclampsia (PE). A systematic search was performed on the PubMed literature database and chain references were retrieved.
Results:
The number of articles retrieved from PubMed was 398. After reading the abstracts, 272 were excluded; of these, six lacked full text in English, 11 were animal studies, 54 were review articles, 19 were abstracts from posters, and 182 were not relevant to the topic. The full texts of 126 articles were read and a further 37 articles were excluded. Thus, 89 studies were identified after reading their full texts. An additional 47 studies were identified based on chain referencing and their full texts were read. The data of a total of 136 studies were entered in the excel datasheets and evaluated. Finally, 25 studies reporting on 13 biomarkers were selected for the meta-analysis.
1. PlGF: In seven studies, the combined effect depicted PlGF was 2.31 times lower in the preeclampsia compared to the controls; p=0.017
2. sFlt: In nine studies, the combined effect showed sFlt was 3.41 times higher in the preeclampsia, compared to the controls; p<0.001
3. sFlt/ PlGF: In four studies, the combined effect model revealed 7.33 times higher value in the preeclampsia compared to the controls; p<0.001
4. sEng: Seven studies evaluated, the combined effect showed sEng to be 2.69 times higher in the preeclampsia; p=0.004
5. HDL: Eight studies evaluated, the pooled effect of HDL displayed a negative effect on the preeclampsia; p=0.011
6. LDL: Five studies analyzed; the pooled effect, 0.317, was not significant; p=0.178
7. Total cholesterol: Four studies assessed, no significant difference between PE and controls, p=0.397
8. Triglycerides: The combined random effect model of seven studies revealed that biomarker was 0.28 times higher in the preeclampsia; p=0.065
9. Adiponectin: Five studies evaluated, 1.89 times lower value in PE; p=0.011.
10. Leptin: Five studies selected, random effect model showed a 1.74 times higher effect of leptin in the preeclampsia, p<0.001
11. APO-A: Four studies were analyzed, no significant difference between the preeclamptic patients and the controls, p=0.175
12. APO-B: In three studies, a significant difference was identified between the preeclamptic patients and the controls, p=0.011
13. TNF: Three studies, no significant difference between the preeclamptic patients and the controls, p=0.84
Conclusion
In this study, the values of the serum biomarkers sFlt, PlGF, sFlt/PlGF, HDL, adiponectin, leptin, triglycerides, and APO-B differed significantly between the preeclampsia patients and the pregnant controls. These findings demand advanced evaluation of biomarkers to enhance the diagnostic screening for preeclampsia.